Format

Send to

Choose Destination
Mol Carcinog. 2019 Sep;58(9):1602-1611. doi: 10.1002/mc.23042. Epub 2019 May 22.

Molecular and immune targets for Merkel cell carcinoma therapy and prevention.

Cohen L1,2, Tsai KY2,3,4.

Author information

1
Department of Dermatology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida.
2
Department of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
3
Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
4
Donald A. Adam Melanoma and Skin Cancer Center of Excellence, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

Abstract

Merkel cell carcinoma (MCC) is a rare neuroendocrine carcinoma of the skin, for which the exact mechanisms of carcinogenesis remain unknown. Therapeutic options for this highly aggressive malignancy have historically been limited in both their initial response and response durability. Recent improvements in our understanding of MCC tumor biology have expanded therapeutic options for these patients, namely through the use of immunotherapies such as immune checkpoint inhibitors. Further elucidation of the tumor mutational landscape has identified molecular targets for therapies, which have demonstrated success in other cancer types. In this review, we discuss both current and investigational immune and molecular targets of therapy for MCC.

KEYWORDS:

Merkel cell carcinoma; immunotherapy; molecular therapy; targeted therapy

PMID:
31116890
DOI:
10.1002/mc.23042

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center